

Formulation and Evaluation of Tramadol HCL Pulsatile Drug Delivery by Using Press Coating Technique

Sriharitha B^{1*}, Preethi J² and Rishpa K³

¹Department of Pharmaceutics, ASN Pharmacy College, Acharya Nagarjuna University, India

²Department of Chemistry, Acharya Nagarjuna University, India

³Department of Industrial Pharmacy, St. Peter's College of Pharmacy, Kakatiya University, India

*Corresponding author: Sriharitha B, Department of Pharmaceutics, ASN Pharmacy College, Acharya Nagarjuna University, Tenali, India, Tel: +91-9492029026; E-mail: ballasriharitha@gmail.com

Received date: May 02, 2017, Accepted date: May 19, 2017, Published date: May 23, 2017

Copyright: © 2017 Sriharitha B, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

The main aim of the present work is to develop and evaluate pulsatile press coated tablets which release total amount of drug at early morning. Here core tablet (180 mg) containing Tramadol hydrochloride 50 mg with excipients crospovidone, sodium starch glycolate and croscarmellose sodium was prepared by direct compression. The core tablet was then coated by coating material composed of combination of polymers hydroxy propyl methyl cellulose (HPMC-K100M) and ethyl cellulose (EC) by press coating technique. Prepared Press Coated tablet was evaluated for all physical tests. *In-vitro* dissolution test was carried out in 0.1 N HCl for first two hrs and 6.8 pH phosphate buffer for remaining period. From that formulations PCF3 containing polymer ratio of (3:1) i.e. HPMC:EC was selected as optimized formulation as it retarded drug release in stomach and shows a drug release with significant lag time. Initially compatibility study was carried out by FTIR showing that all the excipients and polymers were compatible with drug.

Keywords: Pulsatile drug delivery; Press coated tablets; Tramadol hydrochloride; Lag time

Introduction

Controlled drug delivery systems exhibits a major role within the field of pharmaceutical analysis and development sector. Such systems contains temporal control over the release of drug and provides a time period to a drug molecule in terms of controlled drug delivery systems for its advantages of oral route of drug administration. In such systems the drug release starts after its administration similarly occurs in oral administered dosage forms. But due to many chronological conditions there is an urge for time lag in the release of drug (pulse release) that release pattern of the drug is known as pulsatile drug delivery [1-5].

Chronobiology and Chronopharmacotherapy of Disease

Chronotherapy is a medical treatment according to the biological rhythms, in these type of therapeutics delivery of drugs depend on the inherent properties of the drug. The Tradition of prescribing medication at regular time intervals to maintain constant drug levels, in some diseases like Asthama experience symptoms at night, in such conditions administration is coordinated with daylight patterns and biological Rhythms e.g. hydrocortisone and adrenalin secretion [6-10].

Pulsatile Drug Delivery System

Pulsatile drug delivery system shows a rapid release of a few amounts of drug molecules at certain intervals and a little amount at once then, off-release period, i.e., lag time. It aims to release of drug on programmed pattern i.e., release of drug at proper time and at proper

site of action. In this pulsatile drug release system the on single dosage form the initial dose of drug get release followed by one release free interval second dose of drug get release and which is followed by another free interval and pulse of drug release, this kind of release of drug is called as pulse effect and release of drug after a lag time has to be designed [10-15].

Advantages

- Pulsatile delivery shows no side effects
- Extended day and night time activity
- Drug gets adapt to suit circadian rhythms of body functions or diseases, protection from mucosa from effecting drugs, by first pass metabolism drug loss is prevented.

Disadvantages

- No manufacturing reproducibility and efficacy
- Many number of process variables
- Multiple formulation steps
- High cost production
- Need of advanced technology.

Types of Pulsatile Release Systems

Single unit pulsatile systems

Capsular systems: In this capsular systems the capsule is housing a drug with plug and it is enclosed at one end, the plug is made off swellable hydrogel, thus the capsule when contacts with the dissolution media the plug swells pushing itself out of the capsule after a time lag,

followed by spontaneous release of the drug. The plug material consists of polymethacrylates [16,17].

Port systems: In these pore system consist of gelatin capsule coated with semi permeable membrane housing an lipidic plug and an osmotically active agent with drug formulation, when it get contact with aqueous medium, water diffuses across the semi permeable membrane resulting in increased inner pressure that ejects the plug after a time lag.

Reservoir systems: In these reservoir systems reservoir devices coated with a barrier layer and drug is subsequently released rapidly.

Multi-unit pulsatile systems

Reservoir system with rupturable coating: This system consists of small beads, each small bead further comprised of many layers some contain drug substances and some other contains rate controlling polymers, the explosion of formulation can also be achieved through use of swelling agents.

Systems with changed membrane permeability: These systems depends on physio chemical properties of drug and its interaction with the membrane. Eudragit RS or RL and is influenced by the presence of different counter-ions in the release medium [18].

Objective of the Study

To design and characterize an oral, drug delivery system of Tramadol HCl. Tramadol, its O-desmethyl metabolite (M1) are selective, weak OP3-receptor agonists [19].

Based on the concept of press coated technique, time dependent pulsatile controlled drug delivery system was designed.

The drug is contained within the core and separated from the polymers.

The entire core tablet is coated with polymers to prevent the immediate drug release in stomach region.

The press coating prevents disintegration of the soluble core in the gastric fluid.

On reaching the small intestine the tablet will lose its press coat i.e. polymer coat swells to create a lag phase which is required to treat early morning stiffness.

This polymer erodes on swelling and releases the drug from the tablet in the small intestine.

Materials and Methods

Materials

The materials used are Tramadol hydrochloride; Micro crystalline cellulose; Cross povidone; Sodium starch glycolate; Croscarmellose sodium; Mg. stearate; Hydroxy propyl methyl cellulose; Ethyl cellulose; Potassium dihydrogen phosphate; Sodium hydroxide [20-35].

Identification of Tramadol hydrochloride

Examined by infrared spectrum where the spectrum obtained is compared with the standard.

Melting point 171°C and below Figures 1 and 2 are the FTIR results.




Figure 1: IR spectrum of pure drug (Tramadol hydrochloride).




Figure 2: IR spectrum of Tramadol hydrochloride with polymers.

Method of Estimation of Tramadol Hydrochloride

UV spectrophotometric method

The method used in the present study was a UV Spectrophotometric method and is based on the measurement of absorbance at 271 nm in phosphate buffer of 6.8 pH.

Procedure for estimation of Tramadol hydrochloride

25 mg of Tramadol hydrochloride was weighed accurately and dissolved into a small quantity of buffer; finally make up to 25 ml with pH 6.8 phosphate buffer to give a concentration of 1 mg/ml (1000 µg/ml).

From standard solution 5 ml of solution was taken into 50 ml of 6.8 pH phosphate buffer solution to produce 100 µg/ml concentration.

From the above solution 2, 4, 6, 8, 10, 12 ml of the samples were pipette out into 10 ml volumetric flask.

The volume was made up to mark with 6.8 pH buffer solutions to produce concentration as 20, 40, 60, 80, 100 and 120 µg/ml of Tramadol respectively.

The absorbance of prepared solution of Tramadol hydrochloride was measured at 271 nm in Shimadzu UV/Visible 1700 spectrophotometer against blank.

The absorbance data for standard calibration curve are given in Table 1 and plotted graphically. The standard calibration curve yields a straight line, which shows that the drug obeys Beer's law in the concentration range of 20-120 mcg/ml (Figure 3).

Concentration (µg/ml)	Absorbance
20	0.126
40	0.227
60	0.359
80	0.467
100	0.572
120	0.689

Table 1: Absorbance of Tramadol hydrochloride in pH 6.8 phosphate buffer.




Figure 3: Calibration curve.

Formulation Procedure

Formulation for Tramadol core tablet

The inner core tablets were prepared by using direct compression method and the formulation is shown in Table 2. Powder mixtures of Tramadol, microcrystalline cellulose, cross-carmellose, sodium starch glycolate (SSG), and crospovidone were weighed accurately and dry blended for 20 min.

This is followed by the addition of accurately weighed quantity of Magnesium Stearate. This mixture is now further blended for 10 min. 180 mg of resultant powder blend was manually compressed using hydraulic press at a pressure of 1 ton to obtain the core tablet [35-40].

Ingredients	mg/tab (Formulation) (CF----Core Formulation)								
	CF 1	CF2	CF 3	CF 4	CF5	CF6	CF7	CF8	CF9
Tramadol	50	50	50	50	50	50	50	50	50
Mcc	122.6	120.8	119	122.6	120.8	119	122.6	120.8	119
Crospovidone	5.4	7.2	9						
CCS				5.4	7.2	9			
SSG							5.4	7.2	9
Mg. stearate	2	2	2	2	2	2	2	2	2
Total wt	180 mg	180 mg	180 mg	180 mg	180 mg	180 mg	180 mg	180 mg	180 mg

Table 2: Formula of Tramadol core tablet with different excipients.

Formulation of mixed blend for barrier layer

The various formulation compositions containing HPMC and EC. Different compositions were weighed dry blended at about 10 min.

It is used as press-coating material to prepare press-coated pulsatile tablets respectively by direct compression method.

Total weight of Tramadol hydrochloride core tablet=180 mg.

Weight of coating material=400 mg

Total weight of Tramadol hydrochloride press coat tablet=580 mg.

Individual ratios of each ingredient for the formulation of 580 mg of tramadol hydrochloride press coat tablets using different concentrations of excipients are given in the Table 3.

The core tablets were press-coated with 400 mg of mixed blend as given in Table 3. 200 mg of barrier layer material was weighed and transferred into die then the core tablet was placed manually at the center.

Sl. No	Ingredients	PCF1	PCF2	PCF3	PCF4	PCF5
1	HPMC	400	300	200	100	0
2	EC	0	100	200	300	400
3	Total Wt	400 mg	400 mg	400 mg	400 mg	400 mg

Note: PCF-Press Coated Formulation

Table 3: Ratios of each ingredient for the formulation of of tramadol hydrochloride press coat tablets.

The remaining 200 mg of the barrier layer material was added into the die and compressed at a pressure of 5 tons for 3 m in using hydraulic press. Thus formed Tramadol hydrochloride press coated tablets are ready for further tests and *in-vitro* drug release.

Results and Discussion

Weight variation

For tablets weighing 120 mg-300 mg it should be $\pm 7.5\%$ and for tablets weighing more than 300 mg it should be $\pm 5\%$.

The formulated Tramadol hydrochloride press coated tablets was found to be in the prescribed limits and passes the weight variation test and are shown in Tables 4 and 5.

Formulation	Wt. variation	Hardness (kg)	Friability (%)	Thickness (mm)	Disintegration time (min)
F1	179 \pm 2	4 \pm 0.9	0.5 \pm 0.2	2.9 \pm 0.3	3 min 20 sec
F2	181 \pm 3	4.2 \pm 1.3	0.6 \pm 0.1	2.9 \pm 0.4	3 min 22 sec
F3	183 \pm 1	5.7 \pm 0.3	0.4 \pm 0.3	3.2 \pm 0.2	1.10 secmin
F4	183 \pm 2	4.1 \pm 1.1	0.6 \pm 0.1	2.7 \pm 0.3	2 min 35 sec
F5	179 \pm 3	4.3 \pm 1.3	0.7 \pm 0.2	2.4 \pm 0.6	2 min 28 sec
F6	184 \pm 1	4.4 \pm 0.9	0.6 \pm 0.1	2.5 \pm 0.5	1 min 25 sec
F7	181 \pm 2	4.2 \pm 1.5	0.5 \pm 0.3	2.3 \pm 0.5	2 min 45 sec
F8	181 \pm 3	4.3 \pm 1	0.5 \pm 0.2	2.4 \pm 0.7	1 min 40 sec
F9	184 \pm 1	4.4 \pm 1.5	0.5 \pm 0.1	2.6 \pm 0.9	1 min 36 sec

Table 4: Limits of the core Tramadol hydrochloride tablets.

Formulation	Wt. variation	Hardness (kg)	Friability (%)	Thickness (mm)	Swelling index (%)
PCF1	584 \pm 3	6.6 \pm 1.1	0.62 \pm 0.1	6.4 \pm 0.3	280
PCF2	584 \pm 2	5.9 \pm 1	0.42 \pm 0.2	5.7 \pm 0.6	150
PCF3	581 \pm 1	7.5 \pm 0.3	0.69 \pm 0.1	6.7 \pm 0.1	250
PCF4	582 \pm 2	6.3 \pm 1.4	0.49 \pm 0.3	6 \pm 0.7	120
PCF5	581 \pm 2	6.1 \pm 1.5	0.45 \pm 0.3	5.8 \pm 0.8	100

Table 5: Limits of the Tramadol hydrochloride press coated tablets.

Thickness

The thickness variation limits allowed are $\pm 5\%$ of the size of the tablet.

The formulated Tramadol hydrochloride press coated tablets was found to be in the prescribed limits and passes thickness test and are shown in Tables 4 and 5.

Hardness

The acceptable limits of hardness ranges from 4-8 kg/cm².

The formulated Tramadol hydrochloride press coated tablets was found to be in the prescribed limits and are shown in Tables 4 and 5.

Friability

The acceptance limits of weight loss should not be more than 1%.

The formulated Tramadol hydrochloride press coated tablets was found to be in the prescribed limits and are shown in Tables 4 and 5.

Disintegration time for core tablets

Generally the disintegration time for uncoated tablets is 15 minutes.

The formulated Tramadol hydrochloride press coated tablets was found to be in the prescribed limits and are shown in Table 4.

Swelling index for coated tablets

From the results of swelling study it was concluded that swelling increases as the time passes because the polymer gradually absorbed water due to hydrophilic nature and swell. In PCF1 and PCF3 higher swelling index was found.

In PCF1 hydroxy propyl methyl cellulose alone is the polymer and had high swelling index without significant lag time.

But in case of PCF3 HPMC: EC having a ratio of 3:1 shows better swelling index with significant lag time are shown in Table 5.

In-vitro release studies for core tablets

In-vitro results are shown in Tables 6-9 and Figures 4-7.

The results of *In-vitro* dissolution rate studies indicated high dissolution of the drug from all the formulations when compared with pure drug.

Among the formulations prepared formulation with crospovidone (5%) as disintegrant shows highest dissolution rate of 97% at 60 minutes when compared with the other formulations as well as pure drug.

The reason for increase in the dissolution is may be due to high concentration of disintegrants (CP).

Based on the above observations, CP with (5%) was selected for formulation of Tramadol hydrochloride press coated tablets.

Pulsatile drug delivery of Tramadol hydrochloride was developed using different ratios of HPMC and EC as polymers for press coating.

Formulated tablets were subjected to physic chemical evaluation like weight variation, hardness, thickness, friability, swelling index and *in-vitro* drug release.

Time (min)	F1 (3%)	F2 (4%)	F3 (5%)
5	36	32	40
10	42	41	60
15	58	66	73
20	59	73	83
30	78	81	97
45	81	89	97
60	90	90	97

F: Formulation

Table 6: Percentage of drug release with different concentrations of cross povidone.




Figure 4: *In-vitro* Drug release of Cross povidone.

Time (min)	F1 (3%)	F2 (4%)	F3 (5%)
5	25	27	30
10	36	40	42
15	49	52	50
20	55	59	58
30	68	73	67
45	80	78	74
60	90	91	89

F: Formulation

Table 7: Percentage of drug release with different concentrations of caroscarmellose sodium.




Figure 5: *In-vitro* drug release of croscarmellose sodium.

Time (min)	F1 (3%)	F2 (4%)	F3 (5%)
5	22	24	27
10	37	36	41
15	49	51	48
20	59	62	57
30	67	71	72
45	78	82	78
60	86	92	86

F: Formulation

Table 8: Percentage of drug release with different concentrations of Sodium starch glycolate.




Figure 6: *In-vitro* drug release with sodium starch glycolate.

In-vitro dissolution methods for press-coated tablets

Drug release was found to be more with a significant lag time in PCF3 formulation having a ratio of HPMC: EC (3:1). The results are given in the Table 9 and Figure 7. The hydrophilic polymer ethyl

cellulose is responsible for delaying the drug release with significant lag time.

Time (hrs)	PCF1	PCF2	PCF3	PCF4	PCF5
1	0	0	0	0	0
2	0	0	0	0	0
3	19.0	16.4	0	0	0
4	28.5	24.2	12.7	17.3	8.2
5	59.2	37.4	47.3	27.7	19.4
6	73.6	51.2	65.9	48.9	31.3
7	89.7	73.4	84.6	61.0	49.5
8	95.0	88.7	98.2	73.4	65.8

PCF: Press coated formulation

Table 9: Percentage of drug release for press coated tablets.

The decrease in drug release from tablets containing more hydrophobic polymer combination (PCF4 and PCF5) OF HPMC: EC in comparison of tablets containing more hydrophilic polymer combination (PCF1, PCF2 and PCF3) may be attributed to the relatively hydrophobic nature of polymer (EC) which have less affinity for water, this results in decreased drug release.




Figure 7: Drug release for press coated tablets.

The significant lag time is due to hydrophobic nature of ethyl cellulose (EC). Increased drug release rate is due to higher hydrophilic nature of HPMC. Due to its high hydrophilicity it absorbs water and swells resulting in more release of drug from tablets. From the release studies it was observed that combination of high concentration of hydrophilic polymer and low concentration of hydrophobic polymer (HPMC: EC) with a ratio of (3:1) tends to increase the amount of drug release with significant lag time.

Stability studies

Tablets were evaluated for its physico-chemical properties and *in-vitro* dissolution studies after 90 days and there was no significant physico-chemical changes was observed and observed percentage drug

release during 8th hour was 98%. Hence formulation PCF3 was found to be stable during the stability studies.

Drug release kinetics

Tramadol hydrochloride tablets made with hydroxy propyl methyl cellulose and ethyl cellulose were subjected to various kinetic studies like zero order (Cumulative percentage drug released vs. Time), first order (Log cumulative percentage of drug unreleased vs. Time), Higuchi equation (Cumulative percentage of drug unreleased vs. Square root of time) and Korsmeyer's (Log cumulative percentage released vs. Log time) and are reported in Figure 8.

The release kinetics profile of Tramadol hydrochloride tablets was found to obey zero order kinetics and Higuchi.





Figure 8: Drug release kinetics of PCF3.

Conclusion

Consistent lag time with immediate release of the active pharmaceutical ingredient and the requirements for developing the chronotherapeutics was achieved with the developed formulation. At the coating ratio of (3:1) HPMC: EC has been proved as the most appropriate polymer combination for pulsatile drug delivery with a significant lag time and enhanced bioavailability, reduced side effects. Thus this approach of pulsatile release where in tablet of Tramadol hydrochloride is taken at bed time, releasing drug in the morning hours when the symptoms are more prevalent can prove to be a revolution in the treatment of arthritis.

References

1. Yoshizumi Y, Mikushi S, Nakane A, Tohara H, Minakuchi S, et al. (2016) Dynamics of Swallowing Tablets during the Recovery Period following Surgery for Tongue Cancer. *Otolaryngol (Sunnyvale)* 5: 218.
2. Srivastava R, Chaturvedi D (2015) Formulation, Characterization and Evaluation of Gastro-Retentive Floating Tablets of Norfloxacin. *Research & Reviews in Pharmacy and Pharmaceutical Sciences*.
3. Kubo Y, Nogita T, Kimura I, Chiba M, Sakakibara K (2016) Interventional Evaluation of Monoammonium Glycylrhizinate-Glycine/DLMethionine Combination Tablets in Mild Alopecia Areata. *J Clin Exp Dermatol Res* 7: 322.
4. Donthi MR, Dudipala N, Komalla DR, Suram D, Thallapally V, et al. (2015) Design and Evaluation of Floating Multi Unit Mini Tablets (MUMTS) Muco Adhesive Drug Delivery System of Famotidine to Treat Upper Gastro Intestinal Ulcers. *J Pharmacovigil* 3: 179.
5. Belafkih B, Belouafa S, Bennamara A, Skalli A, Abourriche A, et al. (2015) LC-MS/MS Analysis of MDMA in Ecstasy Tablets in Morocco. *J Forensic Res* 6: 301.
6. Vargas M, Bustamante C, Ea V (2015) Bioequivalence Study of Two Formulations Containing Rosuvastatin 40 Mg Tablets in Healthy Colombians. *J Bioequiv Availab* 7: 229-232.
7. Bustami R, Khasawneh S, Absi W, Feddah H, Mroueh M, et al. (2015) Bioequivalence of Losartan/Amlodipine Fixed Dose Combination Tablets (Losanet AM) Compared with Concomitant Administration of Single Components of Losartan and Amlodipine Tablets in Healthy Human Volunteers. *J Bioequiv Availab*.
8. Vargas M, Bustamante C, Villarraga EA (2015) Fed and Fasting Bioequivalence Study for Two Formulations of Bosentan 125 Mg Tablets in Healthy Colombian People. *J Bioequiv Availab* 7: 229-232.
9. Liebowitz MR, Salmán E, Johnso A, Hanover R (2015) A 12-Week Double-Blind, Placebo-Controlled, Flexible-Dose Trial of Desvenlafaxine Extended-Release Tablets in Generalized Social Anxiety Disorder. *J Depress Anxiety* 7: 205-209.
10. Sindhu P (2014) Formulation Development and Evaluation of Bi-Layer Sustained Release Tablets of Amlodipine and Metoprolol. *Journal of Pharmacy and Pharmaceutical Sciences*.
11. Nagashree K (2015) Solid dosage forms: Tablets. *Pharmaceutical analysis*.
12. Sasidhar R (2015) Characterisation of Sustained Release Bilayer Tablets of Pioglitazone and Metformin. *Pharmaceutical analysis*.
13. Sasidhar R (2015) Evaluation of Oral Mucoadhesive Metoprolol succinate Controlled Release Tablets. *Research & Reviews: Journal of Pharmaceutical analysis*.
14. Newton AMJ, Bindu B, Archana C (2016) Comparative Study on Starch Citrate Vs Other Super Disintegrants in the Formulation Characteristics and In vitro Profile of Ondansetron Sublingual Tablets by Direct Compression. *Journal of Pharmacy and Pharmaceutical Sciences*.
15. El Abass SL, Walash MI, Ibrahim F (2016) Development and Validation of Spectrophotometric and Pre-column Derivatization HPLC Method for Determination of Famotidine in Pharmaceuticals by Reaction with Sodium Nitroprusside; Application to Combined Tablets. *Pharm Anal Acta* 7: 476.
16. Gothoskar AV, Joshi AM, Joshi NH (2004) Pulsatile drug delivery systems: a review. *Drug Delivery Technology* 4: 1-11.
17. Shivakumar HG, Pramod kumar TM, Kashppa GD (2003) Pulsatile drug delivery system. *Indian J Pham Educ* 7: 125.
18. Nagar M, Singhai S, Chopra V, Gautam N, Trivedi P (2010) Chronotropic Systems an Emerging Trend in Drug Delivery for Pulsed Release in Chrono pharmacotherapy. *International Journal of Pharmaceutical and Clinical Research* 2: 10-9.
19. Amit K, Sonam R (2011) Pulsatile drug delivery systems: methods and advances. *International Journal of drug formulation and Research* 2: 100-105.
20. Lemmer B (1996) The clinical relevance of chronopharmacology in therapeutic. *Pharmacology Res* 33: 107-115.
21. Sarasija S, Pathak S (2005) Chronotherapeutics: emerging role of biorhythms in optimizing Drug therapy. *Indian J Pharm Sci* 67: 135-140.
22. Janugade BU, Patil SS, Patil SV, Lade PD (2009) Pulsatile drug delivery system for chronopharmacological disorders: an overview. *Journal of pharmacy research* 2: 132-143.
23. Chang RK, Guo X, Burside BA, Couch RA, Rudnic EM (1999) Formulation approaches for oral pulsatile drug delivery. *Amer Pharma Rev* 2: 51-57.
24. Anantha R (2011) Recent advances in oral pulsatile drug delivery. *Journal of Advanced Pharmaceutical Sciences* 1: 58.
25. Walker R, Whittlsea C (2008) Clinical pharmacy and therapeutics. *Elsevier Health Sci (4thedn)*, pp: 759-776.
26. Libo Y, James SC, Joseph AF (2002) Colon specific drug delivery: new approaches and in-vitro/in-vivo evaluation review. *Int J Pharm* 235: 115.
27. Listair CR, Ross JM, Mathias W, Howard NES (2002) Chronopharmaceutical drug delivery from a pulsatile capsule device based on programmable erosion. *J Pharm. Pharmacol* 52: 903-909.
28. Samanta MK, Suresh NV, Suresh B (2000) Development of pulsincap drug delivery of salbutamol sulphate for drug taretting. *Indian Pharma Science* 62: 102-107.
29. Young-II J, Tomoya O, Zhaopeng Hu (2001) Evaluation of an intestinal pressure-controlled colon delivery capsules prepared by dipping method. *J Control Rel* 71: 75-82.
30. Seshasayan A, Sreenivasa RB, Prasanna R, Ramana Murthy KV (2001) Studies on release of Rifampicin from Modified Pulsincap Technique. *Indian J Pharma Sci*: 337-339.
31. Julie B, Howard NES, John ME, Gillian P, Fran MB, et al. (1996) The tolerability of multiple oral doses of Pulsincap capsules in healthy volunteers. *J Control Rel* 38: 151- 158.
32. Sangalli ME, Maroni A, Zema L, Busetti C, Giordano F, et al. (2001) In-vitro and in-vivo evaluation of an oral system for time and/or site-specific drug delivery. *J Control Rel* 73: 103-110.
33. Zahirul MI, Zeljko P, Nevenka K (1999) A pH-dependent colon targeted oral drug delivery system using methacrylic acid copolymers. I. Manipulation of drug release using Eudragit® L100-55 and Eudragit® S100 combinations. *J Control Rel* 58: 215-222.
34. Howard NES, Clive GW, Peter GW, Massoud B, Julei SB, et al. (2002) Evaluation of Pulsincap™ to provide regional delivery of dofetilide to the human GI tract. *Int J pharm* 236: 27-34.
35. Libo Y, James SC, Joseph AF (2002) Colon specific drug delivery: new approaches and in vitro/in vivo evaluation review. *Int J Pharm* 235: 1-15.
36. Matiholimath VS, Dandagi PM, Jain SS, Gadad AP, Kulkarni AR (2007) Time and pH dependent colon specific, pulsatile delivery of theophylline for nocturnal asthma. *Int J Pharm* 328: 49-56.
37. Abraham S, Srinath MS (2007) Development of modified pulsincap drug delivery system of metronidazole for drug targeting. *Indian J Pharm Sci* 69: 18-23.
38. Sungthongjeen S, Puttipatkhachorn S, Paeratakul O, Dashevsky, Bodmeier R (2004) Development of pulsatile release tablets with swelling and rupturable layers. *J Control Rel* : 147-159.
39. Krishnaiah YSR, Raju PV, Kumar BD, Bhaskar P, Satyanarayana V (2001) Development of colon targeted drug delivery systems for Mebendazole. *J Control Rel* 77: 87-95.
40. Satyanarayana S, Rama Prasad YV, Krishnaiah YSR (1996) Trends in colonic drug delivery - a review. *Indian Drugs* 33: 1-10.